Abstract
Despite rigorous efforts to mitigate comorbidities contributing to cardiovascular events, the prevalence of heart disease continues to rise. This report highlights the role of lipoprotein (Lp)(a) a low-density lipoprotein, as a causal risk factor for cardiovascular disease. The impact of Lp(a) on heart disease has been well established, and testing is widely available; yet, screening for Lp(a) continues to be underperformed. The role of Lp(a) in the development of cardiovascular diseases as well as the clinical guidelines for screening patients in primary and secondary prevention populations are reviewed. Finally, clinical practice strategies for patients with elevated Lp(a) are presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
